SPN-817

Drug identity checked against registry records

Also recorded as (-)-Huperzine A extended-release

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyNCT05518578SUPNPhase 2Recruiting2027-12-31Estimated
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresNCT06798896SUPNPhase 2Recruiting2027-08Estimated
SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresNCT07141329SUPNPhase 2Enrolling by invitation2027-12-31Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.